NASDAQ:CALC CalciMedica Earnings Date & Estimates $1.07 -0.05 (-4.46%) Closing price 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CalciMedica is estimated to report earnings on Wednesday, November 11, 2026. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement Announcement DateNovember 11, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from CalciMedicaCalciMedica is expected to post earnings of -$1.2750 per share. In the same quarter a year earlier CalciMedica reported -$1.95 per share. CalciMedica last reported on August 11, 2026, posting -$0.45 per share and beating the -$1.4250 consensus estimate. CalciMedica has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.2750Prior-Year EPS-$1.95Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.45 (Beat by +$0.9750)EPS Beat Rate7 of last 8 quartersPrepare for the Earnings CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ4 2025 Earnings ReportQ3 2025 Earnings Report CalciMedica Earnings FAQ When does CalciMedica report earnings? CalciMedica (NASDAQ:CALC) is estimated to report earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for CalciMedica? Analysts expect CalciMedica to post earnings of -$1.2750 per share for the quarter. CalciMedica Earnings HeadlinesCalciMedica Inc. (NASDAQ:CALC) Receives Consensus Rating of "Hold" from BrokeragesOctober 9, 2026 | americanbankingnews.comCalciMedica (NASDAQ:CALC) Stock Falls 3.8% - Time to Sell?October 6, 2026 | americanbankingnews.comINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.October 14 at 1:00 AM | Paradigm Press (Ad)CalciMedica consensus price target raised 400% to $38.25September 15, 2026 | msn.comCalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | markets.businessinsider.comCalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | globenewswire.comSee More CalciMedica Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email. Email Address About CalciMedicaCalciMedica (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which play a role in the activation of immune cells and the inflammatory response. CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being studied for acute and chronic inflammatory conditions, including severe acute pancreatitis and acute kidney injury associated with severe inflammatory illness. The company has evaluated the therapy in clinical trials and continues to assess its potential applications in diseases with significant unmet medical needs. CalciMedica was founded in 2006 and is headquartered in La Jolla, California. Its development activities have primarily involved clinical research and trials in the United States, with the goal of advancing CRAC channel inhibition into potential treatments for patients with acute inflammatory disorders.View CalciMedica ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
